MX2021003460A - Fabricacion de compuestos y composiciones para inhibir la actividad de shp2. - Google Patents
Fabricacion de compuestos y composiciones para inhibir la actividad de shp2.Info
- Publication number
- MX2021003460A MX2021003460A MX2021003460A MX2021003460A MX2021003460A MX 2021003460 A MX2021003460 A MX 2021003460A MX 2021003460 A MX2021003460 A MX 2021003460A MX 2021003460 A MX2021003460 A MX 2021003460A MX 2021003460 A MX2021003460 A MX 2021003460A
- Authority
- MX
- Mexico
- Prior art keywords
- manufacture
- shp2
- inhibiting
- compositions
- activity
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a un método para la fabricación de un compuesto de Fórmula I o una sal, co-cristal ácido, hidrato u otro solvato del mismo farmacéuticamente aceptable, comprendiendo dicho método hacer reaccionar un compuesto de la fórmula II con un compuesto de la fórmula III de acuerdo con el siguiente esquema de reacción: (ver Fórmulas) en donde LG, A, n, m y p son como se definen en la Breve Descripción de la Invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018108738 | 2018-09-29 | ||
| PCT/IB2019/057863 WO2020065452A1 (en) | 2018-09-29 | 2019-09-18 | Manufacture of compounds and compositions for inhibiting the activity of shp2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003460A true MX2021003460A (es) | 2021-06-18 |
Family
ID=68051872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003460A MX2021003460A (es) | 2018-09-29 | 2019-09-18 | Fabricacion de compuestos y composiciones para inhibir la actividad de shp2. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11873307B2 (es) |
| EP (1) | EP3856744A1 (es) |
| JP (2) | JP7386855B2 (es) |
| KR (1) | KR20210068472A (es) |
| CN (1) | CN112867718A (es) |
| AR (1) | AR116522A1 (es) |
| AU (2) | AU2019346118B2 (es) |
| BR (1) | BR112021005593A2 (es) |
| CA (1) | CA3112322A1 (es) |
| CL (1) | CL2021000737A1 (es) |
| IL (2) | IL281726B2 (es) |
| MX (1) | MX2021003460A (es) |
| TW (1) | TWI829771B (es) |
| WO (1) | WO2020065452A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
| EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| CN111902415A (zh) | 2018-03-02 | 2020-11-06 | 大冢制药株式会社 | 药学化合物 |
| TW202003471A (zh) | 2018-03-21 | 2020-01-16 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| AU2019344897B2 (en) | 2018-09-18 | 2024-01-18 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives AS SRC homology-2 phosphatase inhibitors |
| AU2019346118B2 (en) | 2018-09-29 | 2024-05-16 | Novartis Ag | Manufacture of compounds and compositions for inhibiting the activity of SHP2 |
| US20210346375A1 (en) * | 2018-09-29 | 2021-11-11 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2, as well as products resulting from acid addition |
| EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| TW202126660A (zh) | 2019-09-24 | 2021-07-16 | 美商傳達治療有限公司 | Ｓｈｐ２磷酸酶抑制劑及其製備與使用方法 |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| WO2022006780A1 (en) * | 2020-07-08 | 2022-01-13 | Novartis Ag | Manufacture of compounds and compositions for inhibiting activity of shp2 |
| EP4178962A1 (en) * | 2020-07-08 | 2023-05-17 | Novartis AG | Manufacture of compounds and compositions for inhibiting the activity of shp2 |
| IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
| EP4214209A1 (en) | 2020-09-15 | 2023-07-26 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
| CR20230558A (es) | 2021-05-05 | 2024-01-24 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cáncer |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| BR112023022819A2 (pt) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TW202342040A (zh) | 2022-02-21 | 2023-11-01 | 瑞士商諾華公司 | 藥物配製物 |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN115490697B (zh) * | 2022-11-07 | 2023-09-29 | 西华大学 | 一种手性氮杂螺[4,5]-癸胺的不对称合成方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105899493B (zh) * | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
| JP6523303B2 (ja) | 2014-01-17 | 2019-05-29 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物 |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| ES2824576T3 (es) | 2015-06-19 | 2021-05-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| CN107922388B (zh) | 2015-06-19 | 2020-12-29 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
| US10975080B2 (en) * | 2015-06-19 | 2021-04-13 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| CN109311848B (zh) | 2016-06-07 | 2022-02-01 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| KR102457146B1 (ko) | 2016-06-14 | 2022-10-19 | 노파르티스 아게 | Shp2의 활성을 억제하기 위한 화합물 및 조성물 |
| EP4302834A2 (en) * | 2016-07-12 | 2024-01-10 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| CN110730678B (zh) | 2017-01-10 | 2022-07-15 | 诺华股份有限公司 | 包含alk抑制剂和shp2抑制剂的药物组合 |
| WO2018136265A1 (en) * | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Bicyclic compounds as allosteric shp2 inhibitors |
| US10988466B2 (en) * | 2017-03-23 | 2021-04-27 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic derivatives useful as SHP2 inhibitors |
| KR20200070295A (ko) | 2017-10-12 | 2020-06-17 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 피리딘, 피라진 및 트리아진 화합물 |
| US20210346375A1 (en) | 2018-09-29 | 2021-11-11 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2, as well as products resulting from acid addition |
| AU2019346118B2 (en) | 2018-09-29 | 2024-05-16 | Novartis Ag | Manufacture of compounds and compositions for inhibiting the activity of SHP2 |
| MX2021009563A (es) | 2019-02-12 | 2021-09-08 | Novartis Ag | Combinacion farmaceutica que comprende tno155 y ribociclib. |
| WO2020165733A1 (en) | 2019-02-12 | 2020-08-20 | Novartis Ag | Pharmaceutical combination comprising tno155 and a pd-1 inhibitor |
| US20220152026A1 (en) | 2019-02-12 | 2022-05-19 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| CN111647000B (zh) | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| CN110713447B (zh) | 2019-11-15 | 2021-07-23 | 山东国邦药业有限公司 | 一种对甲硫基苯甲醛的制备方法 |
| KR20220148847A (ko) | 2020-02-28 | 2022-11-07 | 노파르티스 아게 | 다브라페닙, erk 억제제, 및 shp2 억제제를 포함하는 삼중 약학적 조합물 |
| US20230172928A1 (en) | 2020-05-08 | 2023-06-08 | Novartis Ag | Pharmaceutical combination comprising tno155 and nazartinib |
| EP4178962A1 (en) | 2020-07-08 | 2023-05-17 | Novartis AG | Manufacture of compounds and compositions for inhibiting the activity of shp2 |
-
2019
- 2019-09-18 AU AU2019346118A patent/AU2019346118B2/en active Active
- 2019-09-18 EP EP19773559.0A patent/EP3856744A1/en active Pending
- 2019-09-18 BR BR112021005593-2A patent/BR112021005593A2/pt unknown
- 2019-09-18 KR KR1020217011868A patent/KR20210068472A/ko unknown
- 2019-09-18 CN CN201980064337.XA patent/CN112867718A/zh active Pending
- 2019-09-18 IL IL281726A patent/IL281726B2/en unknown
- 2019-09-18 US US17/280,632 patent/US11873307B2/en active Active
- 2019-09-18 CA CA3112322A patent/CA3112322A1/en active Pending
- 2019-09-18 MX MX2021003460A patent/MX2021003460A/es unknown
- 2019-09-18 WO PCT/IB2019/057863 patent/WO2020065452A1/en active Application Filing
- 2019-09-18 JP JP2021516762A patent/JP7386855B2/ja active Active
- 2019-09-26 AR ARP190102733A patent/AR116522A1/es unknown
- 2019-09-27 TW TW108135274A patent/TWI829771B/zh active
-
2021
- 2021-03-24 CL CL2021000737A patent/CL2021000737A1/es unknown
-
2023
- 2023-07-17 IL IL304526A patent/IL304526A/en unknown
- 2023-09-20 JP JP2023152498A patent/JP2024009810A/ja active Pending
-
2024
- 2024-05-02 AU AU2024202897A patent/AU2024202897A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112867718A (zh) | 2021-05-28 |
| JP7386855B2 (ja) | 2023-11-27 |
| KR20210068472A (ko) | 2021-06-09 |
| US20210355134A1 (en) | 2021-11-18 |
| AU2019346118B2 (en) | 2024-05-16 |
| AR116522A1 (es) | 2021-05-19 |
| AU2019346118A1 (en) | 2021-04-01 |
| IL281726A (en) | 2021-05-31 |
| TWI829771B (zh) | 2024-01-21 |
| WO2020065452A1 (en) | 2020-04-02 |
| IL304526A (en) | 2023-09-01 |
| TW202035417A (zh) | 2020-10-01 |
| IL281726B2 (en) | 2024-03-01 |
| BR112021005593A2 (pt) | 2021-06-29 |
| CL2021000737A1 (es) | 2021-10-22 |
| JP2022502388A (ja) | 2022-01-11 |
| JP2024009810A (ja) | 2024-01-23 |
| AU2024202897A1 (en) | 2024-05-23 |
| IL281726B1 (en) | 2023-11-01 |
| EP3856744A1 (en) | 2021-08-04 |
| US11873307B2 (en) | 2024-01-16 |
| CA3112322A1 (en) | 2020-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021003460A (es) | Fabricacion de compuestos y composiciones para inhibir la actividad de shp2. | |
| MX2021003459A (es) | Proceso de fabricacion de un compuesto para la inhibicion de la actividad de shp2. | |
| PH12019502264A1 (en) | Fused imidazo-piperidine jak inhibitors compound | |
| MX2012004382A (es) | Procedimiento para la preparación de compuestos útiles como inhibidores del transportador de glucosa dependiente de sodio 2. | |
| MX363127B (es) | Derivados de benzotiofeno como inhibidores del receptor de estrogeno. | |
| MX2014001671A (es) | Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]- 2-aluiniloxi-etil}-1h[1,2,4]triazol sustituidos. | |
| NZ707389A (en) | Process for preparing bile acid derivatives | |
| MX2014001669A (es) | Compuestos de fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-feni l]-2-alcoxi-2-alquinil/alquenil-etil}-1h-[1,2,4]triazol sustituidos. | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| JO3501B1 (ar) | مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام) | |
| MX2021000348A (es) | 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo. | |
| MX2018001991A (es) | Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa. | |
| IN2014CN04449A (es) | ||
| MX2020002449A (es) | Nuevos compuestos heterociclicos fungicidas. | |
| SA516371323B1 (ar) | مركبات بيرازول فلورو فينيل | |
| MX2022010795A (es) | Hidrato cristalino de un compuesto inhibidor de jak. | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| CR20210394A (es) | Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo | |
| CA2928305C (en) | A crystalline anhydrous form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof | |
| MX2021000611A (es) | Una sal de xinafoato de un compuesto inhibidor de jak. | |
| NZ702684A (en) | Hexadepsipeptide analogues as anticancer compounds | |
| IN2012DN03819A (es) | ||
| MX2021014228A (es) | Formas cristalinas de sal de n-(4-(4 (ciclopropilmetil)piperazin 1- carbonil)fenil)quinolin-8-sulfonamida. | |
| MX2010002475A (es) | Derivados de alquilsulfona. | |
| MX2020001412A (es) | Compuestos y métodos para tratar la hiperpotasemia. |